Abstract
The antigenic phenotype of experimental tumors can be modified through a variety of procedures that either directly — and rather transiently, as a rule — affect the membrane structures of the cell or involve stable, often hereditary, changes in the cell biology (e.g., the genetic code). The term of chemical xenogenization (from the Greek xenos, meaning strange, foreign) was first introduced by our group to indicate the appearance of stable tumor-associated transplantation antigens on murine tumors subjected to chemical treatment and thus rendered antigenically foreign to the host of origin (1). In 1970 Bonmassar et al. (2) had indeed found that murine leukemia cells, on repeated in vivo exposure to the antitumor agent dacarbazine, would become increasingly immunogenic such that they eventually acquired a degree of foreignness capable of conditioning the histocompatible host to reject challenge with the drug-treated tumor.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Puccetti P, Romani L, Fioretti MC: Chemical xenogenization of experimental tumors. Cancer Metast Rev 6: 93–111, 1987.
Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A: Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. Proc Nat Acad Sci (Wash) 66: 1066–1074, 1970.
Fioretti MC, Nardelli B, Bianchi R, Nisi C, Sava G: Antigenic changes of a murine lymphoma by in vivo treatment with triazene derivatives. Cancer Immunol Immunother 11: 283–286, 1981.
Riccardi C, Fioretti MC, Giampietri A, Puccetti P, Goldin A: Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo. Transplantation 25: 63–68, 1978.
Campanile F, Crinò L, Bonmassar E, Houchens D, Goldin A: Radioresistant inhibition of lymphoma growth in congenitally athymic (nude) mice. Cancer Res 37: 394–398, 1977.
Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A: Antigenic changes of L1210 leukemia in mice treated with 5-(3-3’-dimethyl-1-triazeno) imidazole-4-carboxamide. Cancer Res 32: 1446–1450, 1972.
Bonmassar E, Fioretti MC, Nicolin A, Spreafico F: Drug-induced modifications of tumor cell antigenicity. In Spreafico F and Arnon R (eds) Tumor associated antigens and their specific immune response. Academic Press, London, New York, San Francisco, 1979, pp 251–270.
Campanile F, Houchens DP, Gaston M, Goldin A, Bonmassar E: Increased immunogenicity of two lymphoma lines after drug treatment of athymic (nude) mice. J Natl Cancer Inst 55: 207–209, 1975.
Giampietri A, Fioretti MC, Goldin A, Bonmassar E: Drug-mediated antigenic changes in murine leukemia cells: antagonistic effects of quinacrine, an antimutagenic compound. J Natl Cancer Inst 64: 297–301, 1980.
Fioretti MC, Bianchi R, Romani L, Bonmassar E: Drug-induced immunogenic changes of murine leukemic cells: dissociation of onset of resistance and emergence of novel immunogenicity. J Natl Cancer Inst 71: 1247–1251, 1983.
Connors TA, Goddard PM, Merai K, Ross WCJ, Wilman DEV: Tumor inhibitory triazenes: structural requirements for an active metabolite. Biochem Pharmacol 25: 241–246, 1976.
Contessa AR, Giampietri A, Bonmassar A, Goldin A: Increased immunogenicity of L1210 leukemia following short-term exposure to 5(3,3’-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) in vivo or in vitro. Cancer Immunol Immunother 7: 71–76, 1979.
Nardelli B, Contessa AR, Romani L, Sava G, Nisi C, Fioretti MC: Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene-derivatives. Cancer Immunol Immunother 16: 157–161, 1984.
Boon T, Kellermann O: Rejection by syngeneic mice of cell variants obtained by mutagenesis of malignant teratocarcinoma cell line. Proc Natl Acad Sci USA (Wash) 74: 272–275, 1977.
Boon T: Antigenic tumor cell variants obtained with mutagens. Adv Cancer Res 39: 121–151, 1983.
Contessa AR, Bonmassar A, Giampietri A, Circolo A, Goldin A, Fioretti MC: In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3’-dimethyl-1-triazeno)imidazole-4-carboxamide. Cancer Res 41: 2476–2482, 1981.
Nicolin A, Bini A, Coronetti E, Goldin A: Cellular immune response to a drug treated L5178Y lymphoma subline. Nature 251: 654–655, 1974.
Romani L, Fioretti MC, Bonmassar E: In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3’-dimethyl-1-triazeno)imidazole-4-carboxamide in vivo. Transplantation 28: 218–222, 1979.
Santoni A, Kinney Y, Goldin A: Secondary cytotoxic response in vitro against Moloney lymphoma cells antigenically altered by drug treatment in vivo. J Natl Cancer Inst 60: 109–112, 1978.
Romani L, Grohmann U, Fazioli F, Puccetti P, Mage MG, Fioretti MC: Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens. Cancer Immunol Immunother 26: 48–54, 1988.
Romani L, Puccetti P, Fioretti MC, Mage MG: Humoral response against murine lymphoma cells xenogenized by drug treatment in vivo. Int J Cancer 36: 225–231, 1985.
Grohmann U, Puccetti P, Fioretti MC, Mage MG, Romani L: Cell-mediated immunity to chemically xenogenized tumors. III.Generation of monoclonal antibodies interfering with reactivity to novel antigens. Int J Immuno-pharmacol 10: 803–809, 1988.
Testorelli C, Archetti YL, Aresca P, Del Vecchio L: Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline. Cancer Res 45: 5299–5303, 1985.
Grohmann U, Ullrich S, Mage MG, Appella E, Fioretti MC, Puccetti P, Romani L: Identification and immunogenic properties of an 80 kDa surface antigen on a drug-treated tumor variant: relationship to MuLV gp70. Submitted for publication.
Altevogt P, Apt D: High-frequency generation of altered Mr 70 000 env glycoproteins in N-methyl-N’-nitro-N-Nitrosoguanidine. Cancer Res 48: 1137–1142, 1988.
Nicolin A, Spreafico F, Bonmassar E, Goldin A: Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3’dimethyl-1-triazeno)imida-zole-4-carboxamide in vivo. J Natl Cancer Inst 56: 89–93, 1976.
Bianchi R, Romani L, Puccetti P, Fioretti MC: Inhibition of murine lymphoma growth by adoptive transfer of lymhocytes sensitized to a xenogenized tumor variant. Int J Cancer 40: 7–11, 1987.
Keene JA, Forman J: Helper activity is required for in vivo generation of cytotoxic T lymphocytes. J Exp Med 155: 768–782, 1982.
Bianchi R, Romani L, Puccetti P, Fioretti MC: Induction of tumor suppression and delayed-type footpad reaction by transfer of lymphocytes sensitized to a xenogenized tumor variant. Int J Cancer 42: 71–75, 1988.
Puccetti P, Bianchi R, Romani L, Cenci E, Fioretti MC: Delayed-type hypersensitivity to tumor antigens co-expressed with immunogenic determinants induced by xenogenization. Int J Cancer 43: 279–284, 1989.
Fioretti MC, Romani L, Bonmassar A, Taramelli D: Appearance of strong transplantation antigens in non-immunogenic lymphoma following drug treatment in vivo. J Immunopharmacol 2: 189–212, 1980.
Romani L, Grohmann U, Puccetti P, Nardelli B, Mage MG, Fioretti MC: Cell-mediated immunity to chemically xenogenized tumors. II. Evidence for accessory function and self-antigen presentation by a highly immunogenic tumor variant. Cell Immunol 111: 365–378, 1988.
Romani L, Puccetti P, Grohmann U, Cenci E, Mage MG, Fioretti MC: Cell-mediated immunity to chemically xenogenized tumors. IV. Production of lymphokine activity by, and in response to highly immunogenic cells. Int J Immunpharmacol 11: 537–542, 1989.
Puccetti P, Fuschiotti P, Dominici P, Borri-Voltattorni C, Romani L, Fioretti MC: DNA methylating activity in murine lymphoma cells xenogenized by triazene derivatives. Int J Cancer 39: 769–773, 1987.
Fuschiotti P, Fioretti MC, Romani L, Puccetti P: Lack of correlation between DNA-methylating activity and appearance of the immunogenic phenotype in clones of a murine lymphoma treated with mutagens. Cancer Immunol Immunother 29: 139–143, 1989.
Romani L, Bianchi R, Puccetti P, Fioretti MC: Systemic adoptive immunotherapy of a highly immunogenic murine lymphoma growing in the brain. Int J Cancer 31: 477–482, 1983.
Romani L, Nardelli B, Bianchi R, Puccetti P, Mage M, Fioretti MC: Adoptive immunotherapy of intracerebral murine lymphomas: role of different lymphoid populations. Int J Cancer 35: 659–665, 1985.
Giampietri A, Bonmassar A, Puccetti P, Circolo A, Goldin A, Bonmassar E: Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy. Cancer Res 41: 681–687, 1981.
Romani L, Fioretti MC, Bianchi R, Nardelli B, Bonmassar E: Intracerebral immunotherapy of a murine lymphoma antigenically altered by drug treatment in vivo. J Natl Cancer Inst 68: 817–822, 1982.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media New York
About this chapter
Cite this chapter
Puccetti, P. et al. (1990). Xenogenization of Experimental Tumors by Triazene Derivatives. In: Giraldi, T., Connors, T.A., Cartei, G. (eds) Triazenes. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3832-5_6
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3832-5_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6710-9
Online ISBN: 978-1-4615-3832-5
eBook Packages: Springer Book Archive